Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02569398
Registration number
NCT02569398
Ethics application status
Date submitted
5/10/2015
Date registered
6/10/2015
Date last updated
10/02/2020
Titles & IDs
Public title
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
Query!
Scientific title
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia
Query!
Secondary ID [1]
0
0
2015-000948-42
Query!
Secondary ID [2]
0
0
CR107373
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EARLY
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asymptomatic Amyloid-positive
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Dementias
Query!
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Atabecestat, 5 mg
Treatment: Drugs - Atabecestat, 25 mg
Treatment: Drugs - Placebo
Experimental: Group 1 - Participants will receive one atabecestat, 5 milligram (mg) tablet orally once daily up to 54 months.
Experimental: Group 2 - Participants will receive one atabecestat, 25 mg tablet orally once daily up to 54 months.
Experimental: Group 3 - Participants will receive one matching placebo tablet orally once daily up to 54 months.
Treatment: Drugs: Atabecestat, 5 mg
One atabecestat, 5 mg tablet orally once daily up to 54 months.
Treatment: Drugs: Atabecestat, 25 mg
One atabecestat, 25 mg tablet orally once daily up to 54 months.
Treatment: Drugs: Placebo
One matching placebo tablet orally once daily up to 54 months.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Preclinical Alzheimer Cognitive Composite (PACC) Score at Endpoint (Month 24)
Query!
Assessment method [1]
0
0
PACC has 4 components: Free and Cued Selective Reminding Test (0 (worst)-48 (best recall); Delayed Paragraph Recall test (Range 0 (worst)-25 (best recall); Wechsler Adult Intelligence scale: (ranges 0 \[none\]-135 \[best performance\]) and Mini Mental State Examination (Range 0 \[worst\] - 30 \[best performance\]). Component scores are transformed using an established normalization method into z-scores. Each of 4 component change scores is divided by baseline sample standard deviation (SD) of that component. These z scores are summed to form the composite score. Thus, a change of 1 baseline standard deviation on each component would correspond to a 4-point change on the composite. A z-score of 0 is equal to the mean and implies how many SD higher or lower score as compared with baseline score, with increase signifying improvement.
Query!
Timepoint [1]
0
0
Baseline and Endpoint (Month 24)
Query!
Secondary outcome [1]
0
0
Change From Baseline in Cognitive Function Index (CFI) Score at Endpoint (Month 24)
Query!
Assessment method [1]
0
0
The CFI is a modified version of the Mail-in Cognitive Function Screening Instrument, a participant- and informant-reported outcome measure developed by the Alzheimer's Disease Cooperative Study (ADCS). This assessment includes 15 questions (14 of which contribute to the total score, and 1 additional unscored item) that assess the participant's perceived ability to perform high-level functional tasks in daily-life and sense of overall cognitive functional ability. Study participants and their informants independently rate the participant's abilities. A participant-reported and an informant-reported total score is calculated which ranges from 0 to 14 (yes=1; no=0; maybe=0.5 for each question) with higher scores indicating greater impairment.
Query!
Timepoint [1]
0
0
Baseline and Endpoint (Month 24)
Query!
Secondary outcome [2]
0
0
Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living - Prevention Instrument (ADCS-ADLPI) Total Score at Endpoint (Month 24)
Query!
Assessment method [2]
0
0
The Alzheimer's Disease Cooperative Study - Activities of Daily Living -Prevention Instrument (ADCS-ADLPI) is a functional measure composed of 18 items that includes 15 activities of daily living rated on a 4-point scale and 3 high level function items. Study participants and their informants independently rate the participant's level of ability (with no difficulty = 3, with some difficulty = 2, with a lot of difficulty = 1, did not do/don't know = 0). Informants are additionally asked to evaluate whether activities were completed less often, required more time to complete, and if any errors were made performing the task. High-level function items are rated as "yes" or "no". The scores range from 0 to 45 with higher scores indicating less impairment. The total score is the sum of the scores of the 15 activities of daily living questions (range: 0-45) with higher scores indicating less impairment.
Query!
Timepoint [2]
0
0
Baseline and Endpoint (Month 24)
Query!
Secondary outcome [3]
0
0
Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Score at Endpoint (Month 24)
Query!
Assessment method [3]
0
0
RBANS is 20 to 25 minute battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that measure following 5 indices: (1)Attention Index, composed of Digit Span and Coding; (2)Language Index, consisting of Picture Naming and Semantic Fluency subtests; (3)Visuospatial/Construction Index, made up of Figure Copy and Line Orientation subtests; (4)Immediate Memory Index, composed of List Learning and Story Memory subtests, and (5)Delayed Memory Index, consisting of List Recall, List Recognition, Story Recall, and Figure Recall subtests. Completion of RBANS yields 5 index scores based on participant performance on various subtests, as well as a composite Total Index score for battery. Total index scores range from 40 to 160, and are normalized to a mean of 100 and standard deviation (SD) of 15. Higher scores indicate less impairment.
Query!
Timepoint [3]
0
0
Baseline and Endpoint (Month 24)
Query!
Secondary outcome [4]
0
0
Change From Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score at Endpoint (Month 24)
Query!
Assessment method [4]
0
0
The CDR-SB is an interviewer administered scale and impairment is scored in each of categories: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. The 6 individual category ratings, or "box scores", were added together to give the CDR-Sum of Boxes which ranges from 0-18. Higher score indicates severe impairment.
Query!
Timepoint [4]
0
0
Baseline and Endpoint (Month 24)
Query!
Secondary outcome [5]
0
0
Change From Baseline in Neuropsychological Assessment Battery Daily Living Tests (NABDLTs) Score at Endpoint (Month 24)
Query!
Assessment method [5]
0
0
The Neuropsychological Assessment Battery Daily Living Tests (NABDLTs) Score represent a series of performance based measures covering 5 domains (Attention, Memory, Language, Spatial, and Executive function). These are valid, clinically meaningful measures that objectively assess functional deficits. Participant performance scores on NAB subtests are summed, and then normalized to yield an index score. Index scores can range from less than or equal to (\< =) 55 to greater than or equal to (\> =) 145, and are normalized to a mean of 100 and standard deviation of 15. Higher scores indicate less impairment.
Query!
Timepoint [5]
0
0
Baseline and Endpoint (Month 24)
Query!
Eligibility
Key inclusion criteria
* Participant must have a global Clinical Dementia Rating Scale- (CDR) score of '0' at Screening
* Participants 60 to 64 years of age must also have 1 of the following 3 conditions: a) a positive family history for dementia (minimum of 1 first degree relative), b) a previously known apolipoprotein E, e4 allele (APOE ?4) genotype, c) a previously known biomarker status demonstrating elevated amyloid accumulation in cerebrospinal fluid (CSF) or positron emission tomography (PET)
* Participant must be able to read and write and must have adequate hearing and visual acuity to complete the psychometric tests. The legally acceptable representative must also be able to read and write
* Participants must have evidence of amyloid accumulation by means of either: a) low Cerebrospinal Fluid (CSF) ABeta 1-42 levels at Screening; b) a positive amyloid positron emission tomography (PET) scan at Screening (depending on the site's PET capability) by visual read
* Participant must be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at Screening or at Baseline
Query!
Minimum age
60
Years
Query!
Query!
Maximum age
85
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* Participant is receiving an acetylcholinesterase (AChE) inhibitor and/or memantine at any time during Screening or Day 1 predose
* Participant has evidence of any brain diseases, other than potential very early signs of Alzheimer's Dementia (AD) (example. mild hippocampal atrophy) or typical age-related changes (e.g. mild white matter hyperintensity on magnetic resonance imaging [MRI]) or any other abnormality (e.g. folic acid/Vitamin B12 deficiency) that could explain a possible cognitive deficit (including, but not limited to vascular encephalopathy or large strokes (as imaged by cerebral MRI)
* Participant has any contraindications for MRI (example, prostheses, implants, claustrophobia, pacemaker)
* Participant has met criteria for dementia or has a brain disorder that can cause dementia
* Participant has evidence of familial autosomal dominant AD (mutation identified in the family and/or participant prior to randomization)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/10/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
20/12/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
557
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Brisbane
Query!
Recruitment hospital [3]
0
0
- Darlinghurst
Query!
Recruitment hospital [4]
0
0
- East Gosford
Query!
Recruitment hospital [5]
0
0
- Heidelberg
Query!
Recruitment hospital [6]
0
0
- Herston
Query!
Recruitment hospital [7]
0
0
- Subiaco
Query!
Recruitment hospital [8]
0
0
- Tarren Point
Query!
Recruitment hospital [9]
0
0
- Waratah
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Brisbane
Query!
Recruitment postcode(s) [3]
0
0
- Darlinghurst
Query!
Recruitment postcode(s) [4]
0
0
- East Gosford
Query!
Recruitment postcode(s) [5]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [6]
0
0
- Herston
Query!
Recruitment postcode(s) [7]
0
0
- Subiaco
Query!
Recruitment postcode(s) [8]
0
0
- Tarren Point
Query!
Recruitment postcode(s) [9]
0
0
- Waratah
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maine
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Massachusetts
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Michigan
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Mississippi
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Missouri
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nevada
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Ohio
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oregon
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Pennsylvania
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Rhode Island
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
South Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Tennessee
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Texas
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Utah
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Wisconsin
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Antwerpen
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Baudour
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Brussel
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Edegem
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Liège
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Mons
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Gatineau
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Toronto
Query!
Country [41]
0
0
Denmark
Query!
State/province [41]
0
0
Aalborg
Query!
Country [42]
0
0
Denmark
Query!
State/province [42]
0
0
Ballerup
Query!
Country [43]
0
0
Denmark
Query!
State/province [43]
0
0
København Ø
Query!
Country [44]
0
0
Denmark
Query!
State/province [44]
0
0
Rødovre
Query!
Country [45]
0
0
Finland
Query!
State/province [45]
0
0
Kuopio N/a
Query!
Country [46]
0
0
Finland
Query!
State/province [46]
0
0
Turku
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Berlin
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Essen
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Halle
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Homburg
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Kiel
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Mannheim
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Mittweida
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Stuttgart
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
ULM
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Chiba-shi
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Fukuoka-shi
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Hachioji-shi
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Iizuka-shi
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Osaka-shi
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Shibuya-ku
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Shinjuku-ku
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Shirakawa
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Tokyo
Query!
Country [65]
0
0
Mexico
Query!
State/province [65]
0
0
Chihuahua
Query!
Country [66]
0
0
Mexico
Query!
State/province [66]
0
0
Monterrey
Query!
Country [67]
0
0
Mexico
Query!
State/province [67]
0
0
San Luis Potosi
Query!
Country [68]
0
0
Mexico
Query!
State/province [68]
0
0
Tlalnepantla de Baz
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Amsterdam
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Breda
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
s-Hertogenbosch
Query!
Country [72]
0
0
Netherlands
Query!
State/province [72]
0
0
Utrecht
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Barcelona
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Getxo
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Madrid
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Manresa
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
San Sebastian
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Terrassa
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Valencia
Query!
Country [80]
0
0
Sweden
Query!
State/province [80]
0
0
Mölndal
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Birmingham
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
Glasgow
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Guildford
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
London
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Newcastle upon Tyne
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Plymouth
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Swindon
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02569398
Query!
Trial related presentations / publications
Sperling R, Henley D, Aisen PS, Raman R, Donohue MC, Ernstrom K, Rafii MS, Streffer J, Shi Y, Karcher K, Raghavan N, Tymofyeyev Y, Bogert J, Brashear HR, Novak G, Thipphawong J, Saad ZS, Kolb H, Rofael H, Sanga P, Romano G. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA Neurol. 2021 Mar 1;78(3):293-301. doi: 10.1001/jamaneurol.2020.4857.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/98/NCT02569398/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/98/NCT02569398/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02569398
Download to PDF